Company profile for PMV Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combi...
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
8 Clarke Dr., Suite 3 Cranbury, NJ 08512
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186187/0/en/PMV-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Corporate-Highlights.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/10/24/3172959/0/en/PMV-Pharmaceuticals-Announces-Updated-Rezatapopt-Monotherapy-Interim-Data-From-Ongoing-PYNNACLE-Phase-2-Trial-Across-Multiple-Solid-Tumors-With-a-TP53-Y220C-Mutation.html

GLOBENEWSWIRE
24 Oct 2025

https://www.globenewswire.com/news-release/2025/10/13/3165785/0/en/PMV-Pharmaceuticals-to-Present-Rezatapopt-Pivotal-Phase-2-Initial-Analysis-and-Natural-History-Study-Results-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Target.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/09/10/3147627/0/en/PMV-Pharmaceuticals-Announces-Promising-Rezatapopt-Monotherapy-Interim-Data-From-PYNNACLE-Phase-2-Trial-Across-Multiple-Solid-Tumors-With-a-TP53-Y220C-Mutation.html

GLOBENEWSWIRE
10 Sep 2025

https://www.globenewswire.com/news-release/2025/08/07/3129289/0/en/PMV-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Corporate-Highlights.html

GLOBENEWSWIRE
07 Aug 2025

https://www.globenewswire.com/news-release/2025/05/23/3087717/0/en/PMV-Pharmaceuticals-to-Participate-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
23 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty